GSK: approval of Trelegy Ellipta in the US.
(CercleFinance.com) - GlaxoSmithKline (GSK) and its partner Innoviva have announced that the US FDA has approved its FF / UMEC / VI triple therapy (Trelegy Ellipta) for the long-term maintenance treatment of patients with chronic obstructive pulmonary disease.
The pharmaceutical giant says that its Trelegy Ellipta will be available in the US shortly, and points out that applications for authorisation for the product are underway in other areas such as the European Union, Australia and Canada.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The pharmaceutical giant says that its Trelegy Ellipta will be available in the US shortly, and points out that applications for authorisation for the product are underway in other areas such as the European Union, Australia and Canada.
Copyright (c) 2017 CercleFinance.com. All rights reserved.